MSD joins £4.5 million Dementia Consortium

The Dementia Consortium has welcomed MSD (Merck & Co., Inc., Kenilworth, USA) as a new partner in their global venture to accelerate drug discovery for neurodegenerative disease. MSD is the latest pharmaceutical company to join the Dementia Consortium – a £4.5 million charity-industry partnership between Alzheimer’s Research UK, MRC Technology…

Read more >

Dementia Consortium signs new pharmaceutical partner AbbVie

London, UK, North Chicago USA, 16 February 2016: The Dementia Consortium has welcomed AbbVie as new pharmaceutical partner, joining medical research charity MRC Technology, Alzheimer’s Research UK, the UK’s leading dementia research charity, and pharmaceutical companies Astex, Eisai and Lilly. The Consortium is a global £4m collaboration between academia, charity…

Read more >

Dementia Consortium signs new pharma partner Astex Pharmaceuticals

London, UK, 12 October 2015: The Dementia Consortium,a unique charity-private partnership, today announced Astex Pharmaceuticals (Astex) as a new member. The Consortium is a £3.5m cross-sector drug discovery collaboration between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai, Lilly and now Astex. Astex will bring not only knowledge…

Read more >

Dementia Consortium funds project focusing on ALS and FTLD

Project will identify new potential therapeutics for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD) London, UK, 14 September 2015: The Dementia Consortium has awarded £305,000 of funding to a project identifying new therapeutics for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar degeneration (FTLD). A team at the International…

Read more >